The migration and invasion of malignant Glioblastoma (GBM) cells into normal brain parenchyma is fundamentally different than other biological conditions because the biophysical properties of the brain microenvironment are differ from other tissues. These microenvironmental processes contribute to chemotherapy resistance. New microfluidic ex vivo devices, that simulate the microenvironment of tumor cells in the brain, will be used to evaluate the roll of active cell migration through confined spaces in developing treatment resistance by (1) isolating and enriching clonal populations resistant to temozolomide and able to migrate, and (2) testing the roll of candidate genes for chemotherapy resistance. Cell cultures and patient derived stem cell lines will be enriched for migrating and treatment resistance cells to establish clonal populations from heterogeneous cultures. These enrichment techniques will serve as future substrates for treatment resistance models. By preliminary and reported data, ABCG2 is involved in GBM cell migration and treatment resistance. Using the microfluidic channels, the expression pattern and role of ABCG2 will be evaluated for ABCG2 necessity (expression knockdown and inhibitor) and sufficiency (overexpression). We will analyze the expression pattern of ABCG2 to migration, pre-migration, during active migration and post- migration. These results will add to our knowledge of GBM cell migration and establish a platform to test new agents to sensitize migrating cells to conventional treatments.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Exploratory Grants (P20)
Project #
2P20GM103639-06A1
Application #
9573537
Study Section
Special Emphasis Panel (ZGM1)
Project Start
Project End
Budget Start
2018-07-01
Budget End
2019-06-30
Support Year
6
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Oklahoma Health Sciences Center
Department
Type
DUNS #
878648294
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Liu, Xuan; Shen, Tao; Mooers, Blaine H M et al. (2018) Drug resistance profiles of mutations in the RET kinase domain. Br J Pharmacol 175:3504-3515
Boswell-Casteel, Rebba C; Johnson, Jennifer M; Hays, Franklin A (2018) Functional Characterization of the Saccharomyces cerevisiae Equilibrative Nucleoside Transporter 1 (ScENT1). Molecules 23:
Jaiprasart, Pharavee; Yeung, Bertrand Z; Lu, Ze et al. (2018) Quantitative contributions of processes by which polyanion drugs reduce intracellular bioavailability and transfection efficiency of cationic siRNA lipoplex. J Control Release 270:101-113
Buechel, Megan; Dey, Anindya; Dwivedi, Shailendra Kumar Dhar et al. (2018) Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer. Mol Cancer Ther 17:2136-2143
Ha, Ji Hee; Radhakrishnan, Rangasudhagar; Jayaraman, Muralidharan et al. (2018) LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response. Cancer Res 78:1923-1934
Dey, Anindya; Xiong, Xunhao; Crim, Aleia et al. (2018) Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Mol Cancer Ther 17:39-49
Boswell-Casteel, Rebba C; Johnson, Jennifer M; Roe-Žurž, Zygy et al. (2018) Expression and purification of human and Saccharomyces cerevisiae equilibrative nucleoside transporters. Protein Expr Purif 142:68-74
Jiao, Yang; Watts, Tanya; Xue, Jing et al. (2018) Sorafenib and docosahexaenoic acid act in synergy to suppress cancer cell viability: a role of heme oxygenase 1. BMC Cancer 18:1042
Sun, X; Ren, Y; Gunawan, S et al. (2018) Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099. Leukemia 32:1246-1249
Amreddy, Narsireddy; Babu, Anish; Panneerselvam, Janani et al. (2018) Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomedicine 14:373-384

Showing the most recent 10 out of 68 publications